These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 20590580

  • 1. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
    Weger W.
    Br J Pharmacol; 2010 Jun; 160(4):810-20. PubMed ID: 20590580
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY, Chong WS, Tey HL.
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [Abstract] [Full Text] [Related]

  • 3. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M, Costanzo A.
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [Abstract] [Full Text] [Related]

  • 4. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
    Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R.
    J Am Acad Dermatol; 2008 May; 58(5):826-50. PubMed ID: 18423260
    [Abstract] [Full Text] [Related]

  • 5. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR, Emer J.
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [Abstract] [Full Text] [Related]

  • 6. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW.
    Curr Pharm Des; 2014 Aug; 20(4):513-28. PubMed ID: 23565632
    [Abstract] [Full Text] [Related]

  • 7. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
    Campanati A, Molinelli E, Brisigotti V, Offidani A.
    Curr Pharm Biotechnol; 2017 Aug; 18(12):945-963. PubMed ID: 29424306
    [Abstract] [Full Text] [Related]

  • 8. Anti‑cytokine therapy for psoriasis - not only TNF‑α blockers. Overview of reports on the effectiveness of therapy with IL‑12/IL‑23 and T and B lymphocyte inhibitors.
    Wcisło-Dziadecka D, Zbiciak M, Brzezińska-Wcisło L, Mazurek U.
    Postepy Hig Med Dosw (Online); 2016 Dec 08; 70(0):1198-1205. PubMed ID: 28026823
    [Abstract] [Full Text] [Related]

  • 9. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M, Lebwohl M.
    Dermatol Ther; 2009 Dec 08; 22(1):56-60. PubMed ID: 19222517
    [Abstract] [Full Text] [Related]

  • 10. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC.
    Ann Rheum Dis; 2020 Feb 08; 79(2):285-291. PubMed ID: 31672774
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
    Johnsson HJ, McInnes IB.
    Clin Exp Rheumatol; 2015 Feb 08; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
    [Abstract] [Full Text] [Related]

  • 12. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB, Ibler KS.
    J Drugs Dermatol; 2012 Aug 08; 11(8):939-42. PubMed ID: 22859238
    [Abstract] [Full Text] [Related]

  • 13. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K, Deleuran B.
    Ugeskr Laeger; 2008 Jun 09; 170(24):2148-50. PubMed ID: 18565300
    [Abstract] [Full Text] [Related]

  • 14. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Jun 09; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 15. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D, Zbiciak-Nylec M, Brzezińska-Wcisło L, Mazurek U.
    Postgrad Med J; 2016 Mar 09; 92(1085):172-8. PubMed ID: 26719452
    [Abstract] [Full Text] [Related]

  • 16. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M, Dutkiewicz B, Widuchowska M, Kucharz EJ.
    Pol Merkur Lekarski; 2008 Jul 09; 25(145):97-100. PubMed ID: 18839626
    [Abstract] [Full Text] [Related]

  • 17. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
    Mease PJ, Armstrong AW.
    Drugs; 2014 Mar 09; 74(4):423-41. PubMed ID: 24566842
    [Abstract] [Full Text] [Related]

  • 18. Overview of biologic agents in medicine and dermatology.
    Sobell JM.
    Semin Cutan Med Surg; 2005 Mar 09; 24(1):2-9. PubMed ID: 15900793
    [Abstract] [Full Text] [Related]

  • 19. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Yang K, Oak ASW, Elewski BE.
    Am J Clin Dermatol; 2021 Mar 09; 22(2):173-192. PubMed ID: 33301128
    [Abstract] [Full Text] [Related]

  • 20. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S, Thomas BJ, Ciurtin C.
    Rheumatol Int; 2016 May 09; 36(5):603-12. PubMed ID: 26892034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.